tetano
Editor, Senior Moderator
Hum Vaccin Immunother
. 2023 Aug 1;19(2):2245721.
doi: 10.1080/21645515.2023.2245721. Immunogenicity and safety of the quadrivalent inactivated split-virion influenza vaccine in populations aged ≥ 3 years: A phase 3, randomized, double-blind, non-inferiority clinical trial
Jianmin Chen[SUP] 1 [/SUP], Feng Jiang[SUP] 2 [/SUP], Chenyan Zhao[SUP] 3 [/SUP], Jing Chai[SUP] 1 [/SUP], Lanshu Li[SUP] 3 [/SUP], Qinghu Guan[SUP] 2 [/SUP], Xiaoyu Li[SUP] 3 [/SUP], Feiyu Wang[SUP] 1 [/SUP], Ansheng Li[SUP] 4 [/SUP], Hongxia Gao[SUP] 5 [/SUP], Minghui Wang[SUP] 1 [/SUP], Liandi Fu[SUP] 4 [/SUP], Fei Nie[SUP] 1 [/SUP], Weijun Ling[SUP] 6 [/SUP], Haobin Deng[SUP] 7 [/SUP], Lei Zhou[SUP] 1 [/SUP]
Affiliations
This study aimed to evaluate the immunogenicity non-inferiority and safety of the quadrivalent inactivated split-virion influenza vaccine in participants ≥ 3 years old. A total of 3,328 participants were enrolled. Participants 3-8 years old were administered one or two doses of the investigational vaccine or one dose of the control vaccine, whereas the other participants were administered only one dose of the investigational or control vaccine. The immunogenicity and occurrence of adverse events (AEs) after 30 days of full-course vaccination and serious adverse events (SAEs) within 6 months after full-course vaccination were assessed. The sero-conversion rates (SCRs) of anti-H1N1, H3N2, B(Y), and B(V) antibodies in the test group were 74.64%, 87.40%, 82.66%, and 78.89%, respectively, and their geometric mean titers were 1:250.13, 1:394.54, 1:200.84, and 1:94.91, respectively, which were non-inferior to those in the control group. The SCRs and sero-protection rates in the two-dose group of participants 3-8 years old were greater than those in the one-dose group. The incidences of total AEs and adverse reactions in the test group were 31.6% and 21.7%, respectively, which were close to those in the control group. In the two-dose group, the incidence of adverse reactions was considerably lower in the second dose (5.5%) than in the first dose (14.7%). Most AEs were grade 1 in severity, and no SAEs were recorded. The investigational vaccine had immunogenicity non-inferior to the control vaccine, and two doses were more effective than one dose in participants 3-8 years old, with a good overall safety.Trial registration: CTR20200715.
Keywords: Quadrivalent inactivated split-virus influenza vaccine; immunogenicity; non-inferiority; populations ≥ 3 years of age; safety.
. 2023 Aug 1;19(2):2245721.
doi: 10.1080/21645515.2023.2245721. Immunogenicity and safety of the quadrivalent inactivated split-virion influenza vaccine in populations aged ≥ 3 years: A phase 3, randomized, double-blind, non-inferiority clinical trial
Jianmin Chen[SUP] 1 [/SUP], Feng Jiang[SUP] 2 [/SUP], Chenyan Zhao[SUP] 3 [/SUP], Jing Chai[SUP] 1 [/SUP], Lanshu Li[SUP] 3 [/SUP], Qinghu Guan[SUP] 2 [/SUP], Xiaoyu Li[SUP] 3 [/SUP], Feiyu Wang[SUP] 1 [/SUP], Ansheng Li[SUP] 4 [/SUP], Hongxia Gao[SUP] 5 [/SUP], Minghui Wang[SUP] 1 [/SUP], Liandi Fu[SUP] 4 [/SUP], Fei Nie[SUP] 1 [/SUP], Weijun Ling[SUP] 6 [/SUP], Haobin Deng[SUP] 7 [/SUP], Lei Zhou[SUP] 1 [/SUP]
Affiliations
- PMID: 37587615
- DOI: 10.1080/21645515.2023.2245721
This study aimed to evaluate the immunogenicity non-inferiority and safety of the quadrivalent inactivated split-virion influenza vaccine in participants ≥ 3 years old. A total of 3,328 participants were enrolled. Participants 3-8 years old were administered one or two doses of the investigational vaccine or one dose of the control vaccine, whereas the other participants were administered only one dose of the investigational or control vaccine. The immunogenicity and occurrence of adverse events (AEs) after 30 days of full-course vaccination and serious adverse events (SAEs) within 6 months after full-course vaccination were assessed. The sero-conversion rates (SCRs) of anti-H1N1, H3N2, B(Y), and B(V) antibodies in the test group were 74.64%, 87.40%, 82.66%, and 78.89%, respectively, and their geometric mean titers were 1:250.13, 1:394.54, 1:200.84, and 1:94.91, respectively, which were non-inferior to those in the control group. The SCRs and sero-protection rates in the two-dose group of participants 3-8 years old were greater than those in the one-dose group. The incidences of total AEs and adverse reactions in the test group were 31.6% and 21.7%, respectively, which were close to those in the control group. In the two-dose group, the incidence of adverse reactions was considerably lower in the second dose (5.5%) than in the first dose (14.7%). Most AEs were grade 1 in severity, and no SAEs were recorded. The investigational vaccine had immunogenicity non-inferior to the control vaccine, and two doses were more effective than one dose in participants 3-8 years old, with a good overall safety.Trial registration: CTR20200715.
Keywords: Quadrivalent inactivated split-virus influenza vaccine; immunogenicity; non-inferiority; populations ≥ 3 years of age; safety.